Effect of monoamine oxidase inhibitors on metabolism and in vivo release of H 3 -norepinephrine from the hypothalamus.
D000081:Acetamides / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D002396:Catechols / Q000378:metabolism; D003641:Deamination; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008745:Methylation; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009570:Nitriles / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism*; D009647:Normetanephrine / Q000378:metabolism; D010293:Pargyline / Q000494:pharmacology; D010477:Perfusion; D051381:Rats; D013238:Stereotaxic Techniques; D014316:Tritium
D000081:Acetamides; D002396:Catechols; D008996:Monoamine Oxidase Inhibitors; D009570:Nitriles; D009647:Normetanephrine; D014316:Tritium; D010293:Pargyline; D009638:Norepinephrine